Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
285
datasets available to search
ShareScore release 0.9.0
Dataset results
285 results for “regorafenib”
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
ClinicalTrials.gov study NCT07223567. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
ClinicalTrials.gov study NCT05426811. IPD Sharing: NO. Countries: 0. Publications: 0.
A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma
ClinicalTrials.gov study NCT07115550. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
ClinicalTrials.gov study NCT05524155. IPD Sharing: Not stated. Countries: 0. Publications: 0.
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
ClinicalTrials.gov study NCT05993702. IPD Sharing: NO. Countries: 0. Publications: 0.
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
ClinicalTrials.gov study NCT05900648. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
ClinicalTrials.gov study NCT06575725. IPD Sharing: Not stated. Countries: 0. Publications: 0.
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
ClinicalTrials.gov study NCT05025592. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT07137390. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
ClinicalTrials.gov study NCT07078305. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT05730673. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov study NCT06902246. IPD Sharing: NO. Countries: 1. Publications: 0.
HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure
ClinicalTrials.gov study NCT06375317. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
ClinicalTrials.gov study NCT05582031. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib
GEO Series GSE154043. Homo sapiens. 143 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [HNSCC_model]
GEO Series GSE248153. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Circulating microRNA analysis in a prospective co-clinical trial identifies biomarker of response and mechanisms of resistance to regorafenib in colorectal cancer
GEO Series GSE248663. Homo sapiens. 40 samples. Type: Non-coding RNA profiling by array.
RNA-Seq analysis of the effect of regorafenib on melanoma cells
GEO Series GSE273844. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)."
<p><strong>Aim:</strong> Regorafenib may be active in different cancer types. This Phase II trial included patients with various refractory cancer types treated with regorafenib. Here, we report the results of the pancreatic adenocarcinoma cohort. <strong>Methods:</strong> The primary end point was progression-free survival (PFS) rate at 8 weeks; further investigation of regorafenib would be warranted with a PFS rate ≥50%. <strong>Results:</strong> A total of 20 patients were enrolled. The best response was stable disease in four patients (20%). The 8-week PFS rate was 25% with a median PFS of 1.7 months (95% CI: 1.5-2.0). A total of 13 patients (65%) experienced grade 3-4 treatment-related adverse events. <strong>Conclusion:</strong> The study did not meet its primary end point. Further investigation of regorafenib monotherapy in this setting is not recommended. <strong>Clinical Trial Registration:</strong> <a href="http://clinicaltrials.gov/show/NCT02307500">NCT02307500</a>.</p>
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase 2 study
<p><strong>Background</strong></p> <p>Maintaining angiogenesis inhibition and switching the chemotherapy backbone represent the current second-line therapy in patients with <em>RAS</em> mutant metastatic colorectal cancer (mCRC).</p> <p>Regorafenib, an oral multikinase inhibitor, prolonged overall survival (OS) in chemorefractory setting.</p> <p><strong>Methods</strong></p> <p>STREAM was an academic, multicenter, single-arm phase 2 trial, evaluating the activity of regorafenib in <em>RAS</em> mutant mCRC, in terms of the rate of patients who were progression-free after 6months from study entry (6mo-PF). Patients were pretreated with fluoropyrimidine, oxaliplatin and bevacizumab. According to Simon’s two-stage design, ≥ 18 patients 6mo-PF were needed in the overall population (N=46). Secondary endpoints were safety, objective response rate (ORR), progression-free survival (PFS) and OS. Early metabolic response by [18F]-FDG PET/CT scan was an exploratory endpoint. EudraCT Number:2015-001105-13</p> <p><strong>Results</strong></p> <p>The number of patients 6mo-PF was 8/22 at the first stage and 14/46 in the overall population. ORR was 10.9%, Disease Control Rate 54.6%, median (m)PFS 3.6 months (mo) (95%CI 1.9-6.7), mOS 18.9 mo (95%CI 10.3-35.3), mPFS2 (from study entry to subsequent-line progression) was 13.3mo (95%CI=8.4-19.7). Long responders patients (>6mo-PF) significantly more often had a single metastatic site and lung-limited disease. No unexpected toxicity was reported. Grade≥3 events occurred in 39.1% patients, mostly hand-foot syndrome (13%), fatigue and hyperbilirubinemia (6.5%). Baseline metabolic assessment was associated with OS in multivariate analysis, while early metabolic response was not associated with clinical outcomes. </p> <p><strong>Conclusion</strong></p> <p>The study did not meet its primary endpoint. However, regorafenib was well tolerated and did not preclude subsequent treatments. Patients with good prognostic features (single metastatic site and lung-limited disease) reported clinical benefit with regorafenib. The exploratory metabolic analysis suggests that baseline [18F]-FDG PET/CT might be useful to select patients with favorable outcome.</p> <p>A chemotherapy-free interval with regorafenib might be worth of further studies as second-line treatment in selected patients with RAS mutant mCRC.</p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.